Human normal colorectal mucosal cell line (FHC) and 4 human CRC cell lines (SW620, LOVO, SW480, SW116) were used for the study, and all of them were available from ATCC Company (Manassas, VA). DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS and 1% antibiotics were applied for cell culture under 5% CO2 at 37 °C. For treating SW480 and LOVO cells, 2 μg/ml of ActD and DMSO (Mock) were procured from Sigma-Aldrich (St. Louis, MO), while 3 U/μg of RNase R was bought from Epicentre Technologies (Madison, WI). LiCl (5 mg), an activator of the Wnt signaling pathway, was purchased from Med Chem Express (Monmouth Junction, NJ).
Copyright and License information: The Author(s) ©2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.